Clinical Trial

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-21; most recent amendment 2025-10-02.
Status change: Not Yet Recruiting → Recruiting 2025-10-02
Trial Details
NCT Number NCT06997081
Lead Sponsor University of Miami
Collaborators: Pfizer
Conditions Multiple Myeloma
Enrollment 104 participants
Start Date 2025-09-16
Primary Completion 2030-09-30 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-07